Product logins

Find logins to all Clarivate products below.


Ovarian Cancer – Unmet Need – Unmet Need – Advanced Platinum-Sensitive Ovarian Cancer (US/EU)

The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca). With the approval of Lynparza and Zejula in the first-line maintenance setting, PARP inhibitors have become the new standard of care; however, these drugs provide the greatest benefit to patients with BRCA mutations or deficiencies in homologous recombination and have shown limited efficacy in patients without these genetic alterations. Availability of treatment options after disease progression is limited; the FDA’s enhanced scrutiny of PARP inhibitors led to withdrawals and label restrictions, creating further void. In addition, the optimal sequencing of therapies is not clear. A pressing unmet need remains for patients with advanced platinum-sensitive ovarian cancer.

QUESTIONS ANSWERED

  • What are the key factors and goals driving medical oncologists’ prescribing decisions for advanced platinum-sensitive ovarian cancer?
  • How do current therapies, such as Zejula and Lynparza, perform on key clinical attributes in this setting? Are medical oncologists satisfied with the available treatments?
  • What are the most urgent unmet needs in advanced platinum-sensitive ovarian cancer? What are the most attractive opportunities for the development of novel therapies for this disease?
  • What trade-offs are acceptable for U.S. and European physicians across key clinical attributes and price for a new drug for advanced platinum-sensitive ovarian cancer?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 31 European medical oncologists fielded in February 2023.

Key companies: AstraZeneca, GSK, Clovis Oncology

Key drugs: Lynparza, Zejula, Rubraca, bevacizumab

Table of contents


Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…